From Schedule 1 to Schedule 3: What does marijuana rescheduling mean for your organization?
An executive order reclassifying medical marijuana was issued at the end of 2025, marking a historic shift with far-reaching implications for healthcare. Join us as we explore the impact this may have on organizational marijuana policies, employee use, patient care, drug testing, accommodations, HIPAA considerations, and key HR and business decisions so your agency can respond proactively and compliantly.
KEY WEBINAR TAKEAWAYS
BONUS MATERIALS
WEBINAR DETAILS
At year-end 2025, the long-awaited rescheduling of marijuana took a big step forward when President Trump signed an executive order reclassifying medical marijuana from a Schedule 1 drug (on par with heroin) to a Schedule 3 drug (comparable to Tylenol® with Codeine No. 3). Once enshrined as law, the historic rescheduling of medical marijuana will favorably impact the cannabis industry — and potentially could impact hospices and home care companies. This webinar will discuss what marijuana reclassification does (and does not) mean for the healthcare industry. Learn what this rescheduling means (or does not mean) for your organization’s marijuana policy, people, patients, testing program, terminations, accommodations, and other HR, HIPAA, and business issues.
THIS WEBINAR WILL BENEFIT THE FOLLOWING AGENCIES:
WHO SHOULD ATTEND?
TAKE-AWAY TOOLKIT
NOTE: All materials are subject to copyright. Transmission, retransmission, or republishing of any webinar to other institutions or those not employed by your institution is prohibited. Print materials may be copied for eligible participants only.
Presented By
The ePolicy Institute™, Business Writing Institute™ & Marijuana Policy Institute™